Phase 3 Clinical Trials With Primary Completion Dates in December 2023
This is a list of Phase 3 trials with primary completion dates in December 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALVO | Alvotech | 2023-12-01 | Phase 3 | NCT05155293 | Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) |
| ANGO | AngioDynamics, Inc. | 2023-12-01 | Phase 3 | NCT03899636 | A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer |
| ANVS | Annovis Bio, Inc. | 2023-12-01 | Phase 3 | NCT05357989 | A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
| APLT | Applied Therapeutics, Inc. | 2023-12-01 | Phase 3 | NCT04083339 | Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy |
| ASND | Ascendis Pharma A/S | 2023-12-01 | Phase 3 | NCT04615273 | A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency |
| AXSM | Axsome Therapeutics, Inc. | 2023-12-01 | Phase 3 | NCT05113745 | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy |
| AXSM | Axsome Therapeutics, Inc. | 2023-12-01 | Phase 3 | NCT05550207 | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) |
| BFRI | Biofrontera Inc. | 2023-12-01 | Phase 3 | NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). |
| CING | Cingulate Inc. | 2023-12-01 | Phase 3 | NCT05286762 | Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 |
| CYTH | Cyclo Therapeutics, Inc. | 2023-12-01 | Phase 3 | NCT04860960 | Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 |
| CZMWY | Carl Zeiss Meditec AG | 2023-12-01 | Phase 3 | NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme |
| EQ | Equillium, Inc. | 2023-12-01 | Phase 3 | NCT05263999 | A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) |
| FOLD | Amicus Therapeutics, Inc. | 2023-12-01 | Phase 3 | NCT04138277 | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD |
| IONS | Ionis Pharmaceuticals, Inc. | 2023-12-01 | Phase 3 | NCT05139810 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) |
| ITCI | Intra-Cellular Therapies, Inc. | 2023-12-01 | Phase 3 | NCT04959032 | Lumateperone for the Prevention of Relapse in Patients With Schizophrenia |
| IVBXF | Innovent Biologics, Inc. | 2023-12-01 | Phase 3 | NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC |
| MMSI | Merit Medical Systems, Inc. | 2023-12-01 | Phase 3 | NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant |
| MNKD | MannKind Corporation | 2023-12-01 | Phase 3 | NCT04974528 | Afrezza® INHALE-1 Study in Pediatrics |
| RDHL | RedHill Biopharma Ltd. | 2023-12-01 | Phase 3 | NCT04616924 | RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease |
| VNDA | Vanda Pharmaceuticals Inc. | 2023-12-01 | Phase 3 | NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis |